Kaempferol 3-O-sophoroside
Based on 1 Customer Validation
Kaempferol 3-O-sophoroside is an orally active derivative of Kaempferol. It exhibits anti-inflammatory, analgesic, and antidepressant effects. Kaempferol 3-O-sophoroside is an inhibitor of the cell surface receptor toll-like receptor (TLR) 2/4 for High mobility group box 1 (HMGB1), and it also exerts anti-inflammatory effects by blocking the activation of NF-κB expression and the production of TNF-α. Kaempferol 3-O-sophoroside promotes the production of brain-derived neurotrophic factor (BDNF) and enhances autophagy by binding to AMP-activated protein kinase (AMPK), thereby exerting antidepressant effects. Kaempferol 3-O-sophoroside holds promise for research in the fields of inflammation and neurodegenerative diseases.
For research use only. We do not sell to patients.
- Purity : 99.41%
- CAS No.: 19895-95-5
- Formula: C27H30O16
- Molecular Weight:610.52
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All AMPK Isoforms
More
Biological Activity
Description
IC50 & Target
|
TLR2 |
TLR4 |
In Vitro
Kaempferol 3-O-sophoroside (5 μM, 48 h) does not affect the cell viability of human umbilical vein endothelial cells (HUVECs)[1]. Kaempferol 3-O-sophoroside (0-5 μM, 3 h) dose-dependently reduces barrier disruption in lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs), while it does not alter the integrity of the cell barrier when used alone[1]. Kaempferol 3-O-sophoroside (0-5 μM, 24 h) inhibits neutrophil adhesion to lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs) and suppresses neutrophil migration to HUVECs by blocking the activation of NF-κB and the production of TNF-α[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs)
-
Concentration:0.005, 0.05, 0.5, 5 μM
-
Incubation Time:48 h
-
Result:Did not effect cell via- bility At the concentration used (5 μM).
-
Cell Line:Lipopolysaccharide (HY-D1056)-stimulated human umbilical vein endothelial cells (HUVECs)
-
Concentration:0, 0.005, 0.05, 0.5, 5 μM
-
Incubation Time:24 h
-
Result:Inhibited the binding of neutrophils to Lipopolysaccharides (HY-D1056)-stimulated endothelial cells and the transendothelial migration (TEM) of neutrophils.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Acetic acid-induced writhing mice model[4]
-
Dosage:50, 100, 200 mg/kg
-
Administration:Oral gavage (p.o.), administration duration of 30 minutes
-
Result:Caused dose-dependent inhibition of the writhing response induced by acetic acid.
-
Animal Model:Corticosterone (HY-B1618)-induced mouse depression model; Chronic unpredictable mild stress (CUMS) model[3]
-
Dosage:10 and 20 mg/kg
-
Administration:Oral gavage (p.o.), once per day for 20 consecutive days
-
Result:Ameliorated weight loss, dyskinesia, and hippocampal volume reduction induced by Corticosterone and CUMS.
Chemical Information
-
CAS No. 19895-95-5
-
Appearance Solid
-
Molecular Weight 610.52
-
Formula C27H30O16
-
Color Off-white to light yellow
-
SMILES
O=C1C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)=C(C4=CC=C(O)C=C4)OC5=CC(O)=CC(O)=C15
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (163.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.09 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kim TH, et al. Anti-inflammatory effects of kaempferol-3-O-sophoroside in human endothelial cells. Inflamm Res. 2012 Mar;61(3):217-24. [Content Brief]
[2]. Kim T H, et al. Inhibitory effects of kaempferol-3-O-sophoroside on HMGB1-mediated proinflammatory responses[J]. Food and chemical toxicology, 2012, 50(3-4): 1118-1123. [Content Brief]
[3]. Wang R, et al. Kaempferol‐3‐O‐sophoroside (PCS‐1) contributes to modulation of depressive‐like behaviour in C57BL/6J mice by activating AMPK[J]. British journal of pharmacology, 2024, 181(8): 1182-1202. [Content Brief]
[4]. Parveen Z, et al. Antiinflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside[J]. Yakugaku Zasshi, 2007, 127(8): 1275-1279. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6379 mL | 8.1897 mL | 16.3795 mL | 40.9487 mL |
| 5 mM | 0.3276 mL | 1.6379 mL | 3.2759 mL | 8.1897 mL | |
| 10 mM | 0.1638 mL | 0.8190 mL | 1.6379 mL | 4.0949 mL | |
| 15 mM | 0.1092 mL | 0.5460 mL | 1.0920 mL | 2.7299 mL | |
| 20 mM | 0.0819 mL | 0.4095 mL | 0.8190 mL | 2.0474 mL | |
| 25 mM | 0.0655 mL | 0.3276 mL | 0.6552 mL | 1.6379 mL | |
| 30 mM | 0.0546 mL | 0.2730 mL | 0.5460 mL | 1.3650 mL | |
| 40 mM | 0.0409 mL | 0.2047 mL | 0.4095 mL | 1.0237 mL | |
| 50 mM | 0.0328 mL | 0.1638 mL | 0.3276 mL | 0.8190 mL | |
| 60 mM | 0.0273 mL | 0.1365 mL | 0.2730 mL | 0.6825 mL | |
| 80 mM | 0.0205 mL | 0.1024 mL | 0.2047 mL | 0.5119 mL | |
| 100 mM | 0.0164 mL | 0.0819 mL | 0.1638 mL | 0.4095 mL |
Kaempferol 3-O-sophoroside Related Classifications
HY-N2055 Related Classifications
Powered by Bioz